Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 205

1.

Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.

Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M, Fothergill A, Fuller J, Hagen F, Govender N, Guarro J, Johnson E, Lass-Flörl C, Lockhart SR, Martins MA, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Pfaller MA, Schell WA, Trilles L, Kidd S, Turnidge J.

Antimicrob Agents Chemother. 2012 Jun;56(6):3107-13. doi: 10.1128/AAC.06252-11. Epub 2012 Mar 5.

2.

Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.

Espinel-Ingroff A, Aller AI, Canton E, Castañón-Olivares LR, Chowdhary A, Cordoba S, Cuenca-Estrella M, Fothergill A, Fuller J, Govender N, Hagen F, Illnait-Zaragozi MT, Johnson E, Kidd S, Lass-Flörl C, Lockhart SR, Martins MA, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Pfaller MA, Schell WA, St-Germain G, Trilles L, Turnidge J.

Antimicrob Agents Chemother. 2012 Nov;56(11):5898-906. doi: 10.1128/AAC.01115-12. Epub 2012 Sep 4.

3.

In vitro susceptibility testing of amphotericin B for Cryptococcus neoformans variety grubii AFLP1/VNI and Cryptococcus gattii AFLP6/VGII by CLSI and flow cytometry.

Morales BP, Trilles L, Bertho ÁL, Junior IN, de Oliveira Rde V, Wanke B, Lazéra Mdos S.

Mycoses. 2015 May;58(5):273-9. doi: 10.1111/myc.12310. Epub 2015 Mar 10.

PMID:
25756839
4.

Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.

Hagen F, Hare Jensen R, Meis JF, Arendrup MC.

Mycoses. 2016 Sep;59(9):576-84. doi: 10.1111/myc.12507. Epub 2016 Apr 8.

PMID:
27061834
5.

Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method.

Espinel-Ingroff A, Chowdhary A, Gonzalez GM, Guinea J, Hagen F, Meis JF, Thompson GR 3rd, Turnidge J.

Antimicrob Agents Chemother. 2015 Jan;59(1):666-8. doi: 10.1128/AAC.04055-14. Epub 2014 Oct 13.

6.

Identification of novel hybrids between Cryptococcus neoformans var. grubii VNI and Cryptococcus gattii VGII.

Aminnejad M, Diaz M, Arabatzis M, Castañeda E, Lazera M, Velegraki A, Marriott D, Sorrell TC, Meyer W.

Mycopathologia. 2012 Jun;173(5-6):337-46. doi: 10.1007/s11046-011-9491-x. Epub 2011 Nov 13.

PMID:
22081254
7.

Evaluation of antifungal combination against Cryptococcus spp.

Reichert-Lima F, Busso-Lopes AF, Lyra L, Peron IH, Taguchi H, Mikami Y, Kamei K, Moretti ML, Schreiber AZ.

Mycoses. 2016 Sep;59(9):585-93. doi: 10.1111/myc.12510. Epub 2016 May 2.

PMID:
27135278
8.

Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution.

Pfaller MA, Espinel-Ingroff A, Canton E, Castanheira M, Cuenca-Estrella M, Diekema DJ, Fothergill A, Fuller J, Ghannoum M, Jones RN, Lockhart SR, Martin-Mazuelos E, Melhem MS, Ostrosky-Zeichner L, Pappas P, Pelaez T, Peman J, Rex J, Szeszs MW.

J Clin Microbiol. 2012 Jun;50(6):2040-6. doi: 10.1128/JCM.00248-12. Epub 2012 Mar 29.

9.

In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.

Chowdhary A, Randhawa HS, Sundar G, Kathuria S, Prakash A, Khan Z, Sun S, Xu J.

J Med Microbiol. 2011 Jul;60(Pt 7):961-7. doi: 10.1099/jmm.0.029025-0. Epub 2011 Mar 10.

PMID:
21393452
10.

Susceptibility profile of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Uberaba, Minas Gerais, Brazil.

Andrade-Silva L, Ferreira-Paim K, Mora DJ, Da Silva PR, Andrade AA, Araujo NE, Pedrosa AL, Silva-Vergara ML.

Med Mycol. 2013 Aug;51(6):635-40. doi: 10.3109/13693786.2012.761737. Epub 2013 Jan 23.

PMID:
23343452
11.
12.

In vitro susceptibility of Cryptococcus gattii clinical isolates.

Gomez-Lopez A, Zaragoza O, Dos Anjos Martins M, Melhem MC, Rodriguez-Tudela JL, Cuenca-Estrella M.

Clin Microbiol Infect. 2008 Jul;14(7):727-30. doi: 10.1111/j.1469-0691.2008.02021.x.

13.

Molecular typing of clinical isolates of Cryptococcus neoformans/Cryptococcus gattii species complex from Northeast Mexico.

González GM, Casillas-Vega N, Garza-González E, Hernández-Bello R, Rivera G, Rodríguez JA, Bocanegra-Garcia V.

Folia Microbiol (Praha). 2016 Jan;61(1):51-6. doi: 10.1007/s12223-015-0409-8. Epub 2015 Jun 25.

PMID:
26109075
14.

Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.

Córdoba S, Isla MG, Szusz W, Vivot W, Altamirano R, Davel G.

Mycoses. 2016 Jun;59(6):351-6. doi: 10.1111/myc.12479. Epub 2016 Feb 11.

PMID:
26865081
15.

Characterization of clinical isolates of the Cryptococcus neoformans-Cryptococcus gattii species complex from the Amazonas State in Brazil.

Da Silva BK, Freire AK, Bentes Ados S, Sampaio Ide L, Santos LO, Dos Santos MS, De Souza JV.

Rev Iberoam Micol. 2012 Jan-Mar;29(1):40-3. doi: 10.1016/j.riam.2011.05.003. Epub 2011 Jun 2.

PMID:
21699993
16.

Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex.

Trilles L, Meyer W, Wanke B, Guarro J, Lazéra M.

Med Mycol. 2012 Apr;50(3):328-32. doi: 10.3109/13693786.2011.602126. Epub 2011 Aug 23.

PMID:
21859388
17.

Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents.

Aller AI, Martín-Mazuelos E, Gutiérrez MJ, Bernal S, Chávez M, Recio FJ.

J Antimicrob Chemother. 2000 Dec;46(6):997-1000.

PMID:
11102421
18.

Genetic diversity of the Cryptococcus species complex suggests that Cryptococcus gattii deserves to have varieties.

Ngamskulrungroj P, Gilgado F, Faganello J, Litvintseva AP, Leal AL, Tsui KM, Mitchell TG, Vainstein MH, Meyer W.

PLoS One. 2009 Jun 10;4(6):e5862. doi: 10.1371/journal.pone.0005862. Erratum in: PLoS One. 2009;4(7). doi: 10.1371/annotation/348c3375-3918-4e41-bb8c-27aa15d2bdc4. PLoS One. 2009;4(7). doi: 10.1371/annotation/3037bb69-1b8e-4d99-b169-afdf4b74ace2.

19.

In vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotype.

Chong HS, Dagg R, Malik R, Chen S, Carter D.

J Clin Microbiol. 2010 Nov;48(11):4115-20. doi: 10.1128/JCM.01271-10. Epub 2010 Sep 15.

20.

Comparative typing analyses of clinical and environmental strains of the Cryptococcus neoformans/Cryptococcus gattii species complex from Ivory Coast.

Kassi FK, Bellet V, Drakulovski P, Krasteva D, Roger F, Valérie BA, Aboubakar T, Doumbia A, Kouakou GA, Delaporte E, Reynes J, Yavo W, Menan HIE, Bertout S.

J Med Microbiol. 2018 Jan;67(1):87-96. doi: 10.1099/jmm.0.000654. Epub 2017 Dec 7.

PMID:
29214970

Supplemental Content

Support Center